Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-design Study of the Efficacy and Safety of VX-150 for Acute Pain Following Bunionectomy

Next Previous
X
Search
Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-design Study of the Efficacy and Safety of VX-150 for Acute Pain Following Bunionectomy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VX 150 (Primary) ; Hydrocodone/paracetamol
  • Indications Pain
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals

    • Most Recent Events

    • 14 Feb 2018 Primary endpoint (Time-weighted sum of the pain intensity difference between VX-150 versus placebo as recorded on a Numeric Pain Rating Scale (NPRS)-VX-150 compared to placebo) has been met, according to results presented in a Vertex Pharmaceuticals media release.
    • 14 Feb 2018 Results presented in a Vertex Pharmaceuticals media release.
    • 31 Jan 2018 According to a Vertex Pharmaceuticals media release, the company anticipates data from this trial in the first quarter of 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top